Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Blood Cancer J. 2024 Oct 21;14(1):184. doi: 10.1038/s41408-024-01155-y.

¹ NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.
² Sir Charles Gairdner Hospital and Linear Clinical Research, Perth, WA, Australia.
³ Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.
⁴ Royal Adelaide Hospital, Adelaide, SA, Australia.
⁵ Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia.
⁶ GSK, London, UK.
⁷ GSK, Upper Providence, PA, USA.
⁸ GSK, Durham, NC, USA.
⁹ University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia. HANG.QUACH@svha.org.au.

Abstract